**Acknowledgements**

We thank our colleagues for their contribution to the research that resulted in this writing. We thank Dr. Eva Corey and the UW Genitourinary Laboratory for help in the establishment of bladder cancer PDX lines and for donating the LuCaP tumors for study. Our research was supported in part by UW CoMotion Fund, NCI grant U01CA111244, DoD W81XWH-16-1-0614.

**111**

**Author details**

University of Washington, USA

Mary University of London, UK

\*Address all correspondence to: aliu@uw.edu

provided the original work is properly cited.

\*, Tatjana Crnogorac-Jurcevic3

2 Department of Urology, University of Washington, USA

4 Department of Bioengineering, University of Washington, USA

, James J. Lai4

1 Department of Urology and Institute for Stem Cell and Regenerative Medicine,

3 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

and Hung-Ming Lam<sup>2</sup>

Alvin Y. Liu1

*Antibody Therapy Targeting Cancer-Specific Cell Surface Antigen AGR2*

*DOI: http://dx.doi.org/10.5772/intechopen.96492*

*Antibody Therapy Targeting Cancer-Specific Cell Surface Antigen AGR2 DOI: http://dx.doi.org/10.5772/intechopen.96492*
